Clinical Efficacy of Budesonide Combined With Azithromycin in the Treatment of Children With Bronchopneumonia
Objective To investigate the effect of budesonide aerosol inhalation combined with azithromycin on clinical symptoms and inflammatory cytokine levels in children with bronchopneumonia.Methods A total of 75 children with bronchopneumonia admitted to the Affiliated Hospital of Putian University from July 2021 to July 2022 were randomly divided into a control group(n=38)and a observation group(n=37)by random number table method.The control group was treated with azithromycin,while the observation group was treated with budesonide nebulized inhalation combined with azithromycin.The disappearance time of symptoms such as cough,fever,shortness of breath,and cyanosis between two groups were observed and compared,as well as the serum interleukin-6(IL-6)levels,γ interferon(IFN-γ),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)levels,forced vital capacity(FVC),FVC to forced expiratory volume in one second(FEV1/FVC)ratio before and after treatment,and incidence of adverse reactions were recorded.Results The disappearance time of symptoms such as cough,fever,shortness of breath,and cyanosis in the observation group[(3.48±0.68)d,(1.89±0.43)d,(2.68±0.55)d,(4.52±1.17)d]were significantly shorter than those in the control group[(4.08±0.79)d,(2.33±0.66)d,(3.15±0.87)d、(5.23±1.33)d],and there were significant differences between the groups(P<0.05).Before treatment,the cytokine levels in both groups of patients were similar(P>0.05).After treatment,IL-6 and IFN-γ、TNF-α、The CRP levels were significantly reduced(P<0.05),and the levels of IL-6,IFN-γ,TNF-α,and CRP in the observation group[(13.03±2.05)ng/L,(20.21±3.34)pg/mL,(24.34±4.01)ng/mL、(22.36±3.35)mg/L]were lower than those in the control group[(15.12±2.12)ng/L,(22.36±3.73)pg/mL,(28.52±4.72)ng/mL,(25.02±3.88)mg/L],with statistical significance(P<0.05).After treatment,the FEV1 level and FEV1/FVC in the observation group were higher than before treatment,and the observation group[(0.96±0.11)L、(67.68±9.56)%]was better than the control group[(0.88±0.10)L、(62.32±8.62)%],with significant differences(P<0.05).After treatment,it was found that the incidence of adverse reactions during the treatment period in the observation group was 13.51%,and there was no statistically significant difference compared to the control group(10.53%)(P>0.05).Conclusion Budesonide nebulized inhalation combined with azithromycin can effectively control the condition of children with bronchopneumonia,improve lung function,reduce inflammatory factor levels,and the treatment process is safe and reliable.
budesonideazithromycinbronchopneumoniaclinical symptominflammatory indicatorpulmonary function indicatoradverse reaction
NETL
NSTL
万方数据
